Combinatorial therapy of imipridones and histone deacetylase inhibitors in Ewing sarcoma cell lines demonstrates synergistic cell death.

被引：0
|
作者：
Chang, Wen-i [1 ]
Zhou, Lanlan [1 ]
Seyhan, Attila [1 ]
Prabhu, Varun V. [2 ]
El-Deiry, Wafik S. [1 ]
机构：
[1] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA
[2] Oncoceut Inc, Philadelphia, PA USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1060
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro
    Kutko, MC
    Glick, RD
    Butler, LM
    Coffey, DC
    Rifkind, RA
    Marks, PA
    Richon, VM
    LaQuaglia, MP
    CLINICAL CANCER RESEARCH, 2003, 9 (15) : 5749 - 5755
  • [42] Overcoming resistance to EGFR inhibitors in NSCLC cell lines by sequential treatment with histone deacetylase inhibitors.
    Witta, SE
    Helfrich, B
    Chan, D
    Hirsch, F
    Franklin, W
    Drabkin, HA
    Gemmill, RM
    Bunn, PA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 641S - 641S
  • [43] Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models
    Liu, Shuzhen
    Cheng, Hongwei
    Kwan, Wanda
    Lubieniecka, Joanna M.
    Nielsen, Torsten O.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (06) : 1751 - 1761
  • [44] Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors
    Ouaissi, M.
    Cabral, S.
    Tavares, J.
    da Silva, A. Cordeiro
    Mathieu-Daude, F.
    Mas, E.
    Bernard, J. P.
    Sastre, B.
    Lombardo, D.
    Ouaissi, Ali
    CANCER BIOLOGY & THERAPY, 2008, 7 (04) : 523 - 531
  • [45] Transcription therapy for cancer: Effects of histone deacetylase (HDAC) inhibitors on proliferation, apoptosis and differentiation of leukemic cell lines.
    He, LZ
    Tolentino, T
    Warrell, RP
    Zelent, A
    Rifkind, RA
    Marks, PA
    Richon, VM
    Pandolfi, PP
    BLOOD, 1998, 92 (10) : 510A - 510A
  • [46] Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis
    Berghuis, Dagmar
    Schilham, Marco W.
    Vos, Hanneke I.
    Santos, Susy J.
    Kloess, Stephan
    Buddingh, Emilie P.
    Egeler, R. Maarten
    Hogendoorn, Pancras C. W.
    Lankester, Arjan C.
    CLINICAL SARCOMA RESEARCH, 2012, 2
  • [47] Synergistic interactions between sapacitabine (CYC682) and inhibitors of either histone deacetylase or methyltransferase in Acute Myeloid Leukemia cell lines
    Green, Simon
    MacKay, Ruth
    MacCallum, David
    Melville, Jean
    Frame, Sheelagh
    Fleming, Ian
    CANCER RESEARCH, 2009, 69
  • [48] The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines
    Cosenza, Maria
    Civallero, Monica
    Fiorcari, Stefania
    Pozzi, Samantha
    Marcheselli, Luigi
    Bari, Alessia
    Ferri, Paola
    Sacchi, Stefano
    CANCER BIOLOGY & THERAPY, 2016, 17 (10) : 1094 - 1106
  • [49] Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib
    Mattias K Andersson
    Pierre Åman
    Cancer Cell International, 8
  • [50] Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib
    Andersson, Mattias K.
    Aman, Pierre
    CANCER CELL INTERNATIONAL, 2008, 8 (1)
12345